"Phase I Oncology Clinic and Application Lab - focusing on Solid Tumor Immunotherapy and Cell Therapy/CDMO Services"

During the past decade, Carolina BioOncology Institute conducted 40 clinical trials. In the 10-year time frame, 40 clinical trials started and 6 clinical trials were completed, i.e. on average, 15% percent of trials that started reached the finish line to date. In the past 5 years, 24 clinical trials started and 2 clinical trials were completed. i.e. 8.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Carolina BioOncology Institute" #1 sponsor was "Bristol-Myers Squibb" with 7 trials, followed by "MacroGenics" with 6 trials sponsored, "Arcus Biosciences, Inc." with 4 trials sponsored, "Calico Life Sciences LLC" with 2 trials sponsored and "Incyte Biosciences International Sàrl" with 2 trials sponsored. Other sponsors include 29 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Carolina BioOncology Institute" #1 collaborator was "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "AbbVie" with 2 trials as a collaborator, "TopAlliance Biosciences, Inc." with 2 trials as a collaborator, "CSPC ZhongQi Pharmaceutical Technology Co., Ltd." with 1 trials as a collaborator and "CTI Clinical Trial and Consulting Services" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Carolina BioOncology Institute" are "Ovarian Cancer" (11 trials), "Advanced Solid Tumor" (8 trials), "Breast Cancer" (8 trials), "Colorectal Cancer" (8 trials) and "Pancreatic Cancer" (7 trials). Many other conditions were trialed in "Carolina BioOncology Institute" in a lesser frequency.

Most popular intervention types in "Carolina BioOncology Institute" are "Drug" (40 trials), "Biological" (15 trials), "Combination Product" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (6 trials), "Nivolumab" (4 trials), "Carboplatin" (3 trials), "Docetaxel" (3 trials) and "Ipilimumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Carolina BioOncology Institute" are 52 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Carolina BioOncology Institute". undefined are not yet recruiting, 24 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Carolina BioOncology Institute, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Carolina BioOncology Institute, 48 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".